Vessella RL - Search Results

1

Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues.

Canada AT, Roberson KM, Vessella RL, Trump DL, Robertson CN, Fine RL. Canada AT, et al. Among authors: vessella rl. Biochem Pharmacol. 1996 Jan 12;51(1):87-90. doi: 10.1016/0006-2952(95)02157-4. Biochem Pharmacol. 1996. PMID: 8534273 Free article.

2

Preclinical models of prostate cancer.

Royai R, Lange PH, Vessella R. Royai R, et al. Semin Oncol. 1996 Dec;23(6 Suppl 14):35-40. Semin Oncol. 1996. PMID: 8996584 Review.

3

Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.

Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL, Belldegrun AS, Hood LE. Liu AY, et al. Among authors: vessella rl. Prostate. 2004 Jul 1;60(2):98-108. doi: 10.1002/pros.20031. Prostate. 2004. PMID: 15162376

4

A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R. True LD, et al. Am J Pathol. 2002 Aug;161(2):705-15. doi: 10.1016/S0002-9440(10)64226-5. Am J Pathol. 2002. PMID: 12163395 Free PMC article.

5

Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration.

Liu AY, Corey E, Bladou F, Lange PH, Vessella RL. Liu AY, et al. Among authors: vessella rl. Int J Cancer. 1996 Jan 3;65(1):85-9. doi: 10.1002/(SICI)1097-0215(19960103)65:1<85::AID-IJC15>3.0.CO;2-H. Int J Cancer. 1996. PMID: 8543402

6

Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid.

Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P. Dahiya R, et al. Among authors: vessella rl. Int J Cancer. 1994 Oct 1;59(1):126-32. doi: 10.1002/ijc.2910590122. Int J Cancer. 1994. PMID: 7523313

7

Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. Ellis WJ, et al. Among authors: vessella rl. Clin Cancer Res. 1996 Jun;2(6):1039-48. Clin Cancer Res. 1996. PMID: 9816265

8

VCaP, a cell-based model system of human prostate cancer.

Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ. Korenchuk S, et al. In Vivo. 2001 Mar-Apr;15(2):163-8. In Vivo. 2001. PMID: 11317522

9

Study of free and complexed prostate-specific antigen in mice bearing human prostate cancer xenografts.

Buhler KR, Corey E, Stray JE, Vessella RL. Buhler KR, et al. Among authors: vessella rl. Prostate. 1998 Aug 1;36(3):194-200. doi: 10.1002/(sici)1097-0045(19980801)36:3<194::aid-pros8>3.0.co;2-h. Prostate. 1998. PMID: 9687992

10

NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH. Moul JW, et al. Among authors: vessella rl. Urology. 2012 Dec;80(6):1319-25. doi: 10.1016/j.urology.2012.06.080. Epub 2012 Oct 26. Urology. 2012. PMID: 23107099 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

327 results

Search Page

Filters